NCT06207708Recruiting

Sarcopenia in Head and Neck Cancer Patients Treated With Curative Hadrontherapy

Name: Clinical Trial NCT06207708
Creator: CNAO National Center of Oncological Hadrontherapy
Keywords: Head and Neck Cancer, questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement, other, clinical trial, Italy

Role of Baseline Sarcopenia in Determining Acute Toxicity for Head and Neck Cancer Patients Treated With Curative Hadrontherapy: a Prospective Monoinstitutional Study

CNAO National Center of Oncological HadrontherapyClinicalTrials.govother

Verified

Study focus

Disease/Condition: Head and Neck Cancer
Drug/Device/Intervention: questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement
Study type: Observational
Intervention type: other

Sponsor & location

Primary sponsor: CNAO National Center of Oncological Hadrontherapy
Location: Pavia, Italy

Timeline & enrollment

Phase: N/A
Start date: Apr 18, 2023
End date: Nov 18, 2024
Enrollment: 70 participants

Primary outcome

skeletal muscle strength mass (SMM)

Summary

The study focuses on the impact of sarcopenia on acute and late toxicities in head and neck tumor affected patients treated with particle therapy.

ICD-10 classifications

Malignant neoplasm of other and ill-defined sites: Head, face and neckMalignant neoplasm: Skin of scalp and neckMalignant neoplasm: Connective and soft tissue of head, face and neckCarcinoma in situ: Skin of scalp and neckSecondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06207708
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06207708 through Pure Global AI's free database. This phase not specified trial is sponsored by CNAO National Center of Oncological Hadrontherapy and is currently Recruiting. The study focuses on Head and Neck Cancer. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.